Genprex Sets 1:22 Reverse Split Effective July 16 to Fight Nasdaq Delisting
GNPX sits 28% above its 52-week low of $0.423 on light trading volume (0.2× avg).
Summary
Genprex will implement a 1:22 reverse stock split on July 16, 2026, to regain Nasdaq compliance after receiving a delisting notice. The split reduces outstanding shares to ~504,936 but does not alter the company's market cap or financial distress.
Key Events · Corporate Governance and Compliance · GNPX
-
1:22 Reverse Stock Split Announced
On July 2, 2026, the board approved a 1:22 reverse split, effective July 16, 2026, reducing outstanding shares from ~11.1 million to ~504,936.
-
Nasdaq Delisting Threat
The reverse split aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement after a delisting notice received on June 10, 2026.
-
Post-Split Price Uncertainty
The company warns that the reverse split may not sustain a $1+ share price, and delisting could materially harm its ability to raise capital.
-
Clinical Trial Updates in Investor Presentation
The furnished presentation includes updates on Acclaim-1 and Acclaim-3 trials, with Phase 2 enrollment ongoing and interim analyses expected in 2027.
Analysis · GNPX · Life Sciences
To regain compliance with Nasdaq's $1.00 minimum bid price requirement, Genprex is executing a 1:22 reverse stock split on July 16, 2026. The company received a delisting notice in June, and shareholders approved a reverse split range of 1:5 to 1:50 on June 18. Within that authority, the board selected a 1:22 ratio, which will reduce outstanding shares from ~11.1 million to ~504,936. While the split mechanically boosts the share price, it does not change the company's market cap or underlying fundamentals. Genprex remains under going-concern warnings and has been funding operations through dilutive ATM sales. The filing also includes an investor presentation with clinical updates, but the reverse split is the market-moving event. If the post-split price fails to hold above $1, delisting remains a risk, which would further impair the company's ability to raise capital.
At the time of this filing, GNPX was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.42 to $55.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.